This session delves into methods to improve study outcomes by combining scientific rigor with a commercially driven mindset, ensuring that clinical development meets the expectations of payers, health technology assessment requirements, and considerations of real-world evidence (RWE).
Furthermore, we will address the crucial function of real-world data (RWD), real-world evidence in enhancing clinical trial results, supporting market surveillance, long-term value for payers.
May 5, 14:30 - 15:15, room MCH Lounge
| Name | Position | Institution |
|---|---|---|
| Laura Vidal Boixader | Vice President, Therapeutic Strategy Leader | Fortrea |
| Name | Position | Institution |
|---|---|---|
| John Doyle | Chief Scientific Officer | Fortrea |
| Juliane Bernholz | CEO | AM-Pharma |
| Adrian Cassidy | GMA Evidence Generation Head | Novartis AG |
Fortrea (Nasdaq: FTRE): a leading global provider of clinical development solutions. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trials, clinical pharmacology, technology enabled trial solutions and post-approval services.
